Targeted & controlled bone healing

Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

The past twenty years have seen a number of advancements in bone repair, from the increasing use of bioactive scaffolds to the introduction of growth factors and cell-based allografts. Current bone graft selection includes autograft, allograft, demineralized bone matrix, ceramics, mesenchymal stem cells, and recombinant human bone morphogenetic protein. Each pose their respective advantages and disadvantages and are the focus of ongoing research investigating the safety and efficacy of their use.

The scientific leaders at Kuros have spent more than a decade advancing the science of orthobiologics by refining technologies that instruct the body to form bone in a targeted and controlled fashion.

Kuros Biosciences, a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), together with the University of Zürich and at the California Institute of Technology (CalTech) developed the proprietary 'TG Hook technology' which led to our biologics program. In early 2017 Kuros acquired Xpand Biotechnology, adding substantial expertise in the surface science of orthobiologics & delivering the next generation MagnetOs family of bone grafts to our portfolio.

Along that journey we have confirmed our position as scientific leaders and orthobiologics experts through the accumulation of:

> Over 600 patients enrolled in multinational clinical trials
> 150 years combined orthobiologics research experience amongst our team
> 78 patents and patents pending 

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Overview

Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

The past twenty years have seen a number of advancements in bone repair, from the increasing use of bioactive scaffolds to the introduction of growth factors and cell-based allografts. Current bone graft selection includes autograft, allograft, demineralized bone matrix, ceramics, mesenchymal stem cells, and recombinant human bone morphogenetic protein. Each pose their respective advantages and disadvantages and are the focus of ongoing research investigating the safety and efficacy of their use.

The scientific leaders at Kuros have spent more than a decade advancing the science of orthobiologics by refining technologies that instruct the body to form bone in a targeted and controlled fashion.

Kuros Biosciences, a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), together with the University of Zürich and at the California Institute of Technology (CalTech) developed the proprietary 'TG Hook technology' which led to our biologics program. In early 2017 Kuros acquired Xpand Biotechnology, adding substantial expertise in the surface science of orthobiologics & delivering the next generation MagnetOs family of bone grafts to our portfolio.

Along that journey we have confirmed our position as scientific leaders and orthobiologics experts through the accumulation of:

> Over 600 patients enrolled in multinational clinical trials
> 150 years combined orthobiologics research experience amongst our team
> 78 patents and patents pending